Human papillomavirus. Global trends in disease prevention (Review)

Purpose of the review: Assess global trends in the prevention of HPV development.

Materials and methods: The following databases were searched and analyzed: PubMed, Embase, Cochrane Library and Google Academy.

Results: Current evidence suggests that human papillomavirus (HPV) infection rates are higher in developing regions. The main risk group for HPV infection are sexually active young females and adolescents. It has been shown that in order to combat HPV effectively, it is advisable to carry out mass vaccination of young females and boys before their first sexual contact. Also, vaccination of other age groups shows positive dynamics in the fight against HPV-associated diseases. To date, there are six licensed HPV prophylactic vaccines comparable in effectiveness.

Conclusion: The main strategy for the prevention of cervical cancer should be to vaccinate teenagers before their first sexual contact. Vaccination against human papillomavirus has been proven to prevent precancerous conditions of the cervix, as well as other diseases associated with HPV infection.

1. Kombe Kombe AJ, Li B, Zahid A, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021;8:552028.

2. Ziganshin AM, Keidar SV, Khalitova RSh, et al. Human papillomavirus: etiology, pathogenesis, role and significance in the development of cervical cancer. Gynecology. 2023;25(1):17—21. (In Russ).

3. De Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664—670.

4. Moscicki AB. Management of adolescents who have abnormal cytology and histology. Obstet Gynecol Clin North Am. 2008;35(4):633—643.

5. Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115.

6. Hoffman BL, Schorge JO, Bradshaw KD, et al. Williams Gynecology. 4th ed. New York: McGraw-Hill; 2020.

7. Adamyan LV, Apolikhina IA, Artymuk NV, et al. Cervical intraepithelial neoplasia, erosion and ectropion of the cervix: clinical recommendations. Moscow: Ministry of Health of Russia; 2020. (In Russ).

8. Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030— 4039.

9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7—34.

10. WHO’s certified. International Agency for Research on Cancer: Cancers attributable to infections in 2020. Available at: https://gco.iarc.fr/causes/infections/tools-pie?mode=&sex=2&population=hdi&continent=0&country=0&population_group=0&cancer=0&key=attr_cases&lock_scale=0&pie_mode=1&nb_results=5 (cited 2024 Jul 5).

11. Belotserkovtseva LD, Mayer YuI, Kharkovskaya MN. Vaccination of adolescents against HPV in the prevention of cervical cancer and other virus-associated diseases of the vulva and vagina. Bulletin of Surgut State University. Medicine. 2010;4:91—96. (In Russ).

12. Karachentsova IV, Sibirskaya EV, Denisovets VM, Chernysheva MYu, Nurmatova AF. Routes of HPV infection in girls of different ages. Children's Infections. 2025;24(1):37—42. (In Russ).

13. Sharkov SM, Sibirskaya EV, Tarbaya NO, Shchukina ND. Organization of measures for prevention and early diagnosis of gynecological diseases in children and adolescents. Russian Pediatric Journal. 2019;22(1):38—41. (In Russ).

14. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37(6):S3—S9.

15. Crochard A, Luyts D, di Nicola S, et al. Self-reported sexual debut and behavior in young adults aged 18—24 years in seven European countries: implications for HPV vaccination programs. Gynecol Oncol. 2009;115(3):S7—S14.

16. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10(2):101— 106.

17. Dubbink JH, van der Eem L, McIntyre JA, et al. Sexual behaviour of women in rural South Africa: a descriptive study. BMC Public Health. 2016;16:557.

18. Delprato M, Akyeampong K. The Effect of Early Marriage Timing on Women's and Children's Health in Sub-Saharan Africa and Southwest Asia. Ann Glob Health. 2017;83(3-4):557—567.

19. Luhn P, Walker J, Schiffman M, et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 2013; 128(2):265—270.

20. Houlihan CF, Baisley K, Bravo IG, et al. Rapid acquisition of HPV around the time of sexual debut in adolescent girls in Tanzania. Int J Epidemiol. 2016;45(3): 762—773.

21. Cervical cancer. World Health Organization; 2024 Mar 5. Switzerland. Available at: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer (cited 2024 Jul 5).

22. Sibirskaya EV, Nikiforova PO, Koryagina OS, et al. The influence of high-risk human papillomavirus on the development of CIN and cervical cancer in sexually active adolescents and young women. Effective Pharmacotherapy. 2023;19(37):40—43. (In Russ).

23. HPV information center. Human Papillomavirus and Related Diseases Report. Barcelona: BMJ books; 2023.

24. Tan SC, Ismail MP, Duski DR, et al. Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. Biosci Rep. 2018;38(2):BSR20171268.

25. Valasoulis G, Pouliakis A, Michail G, et al. The Influence of Sexual Behavior and Demographic Characteristics in the Expression of HPV-Related Biomarkers in a Colposcopy Population of Reproductive Age Greek Women. Biology (Basel). 2021;10(8):713.

26. Itarat Y, Kietpeerakool C, Jampathong N, et al. Sexual behavior and infection with cervical human papillomavirus types 16 and 18. Int J Womens Health. 2019;11:489—494.

27. Moore G, Fetterman B, Cox JT, et al. Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. J Low Genit Tract Dis. 2010;14(2):97—102.

28. Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2020;65:98—108.

29. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602—608.

30. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. World Health Organization; 2022 Apr 11. Switzerland. Available at: https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer (cited 2024 Jul 5).

31. Williamson AL. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. 2023;15(7):1440.

32. Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? Oral Oncol. 2021;115:105168.

33. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069.

34. Drolet M, Bénard É, Pérez N, et al.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497—509.

35. Eun TJ, Perkins RB. Screening for Cervical Cancer. Med Clin North Am. 2020;104(6):1063—1078.

36. Shu Y, Yu Y, Ji Y, et al. Immunogenicity and safety of two novel human papillomavirus 4and 9-valent vaccines in Chinese women aged 20—45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial. Vaccine. 2022;40(48):6947—6955.

37. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41):1700737.

38. Latsuzbaia A, Arbyn M, Tapp J, et al. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg. Cancer Epidemiol. 2019;63:101593.

39. Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597—1601.

40. Bakhtiyarov KR, Shchukina AS. Human papillomavirus — a modern view of the problem. Medical and Pharmaceutical Journal «Pulse». 2017;19(12):37—42. (In Russ).

41. Bankhead C. HPV Vaccination Reduces Risk of Multiple Types of Cancer in Men and Women — Large cohort study provides some of the first evidence of cancer reduction after vaccination. MedPage Today; 2024 May 24. USA. Available at: https://www.medpagetoday.com/meetingcoverage/asco/110334 (cited 2024 Jul 5).

42. Mann LM, Llata E, Flagg EW, et al. Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010—2016. J Infect Dis. 2019;219(9):1389—1397.

43. Karachentsova IV, Sibirskaya EV, Fomina MM, et al. State of the reproductive system of adolescent girls after vaccination against human papillomavirus using a quadrivalent vaccine. Pediatric Pharmacology. 2024;21(2):111—118. (In Russ).

44. Kalyuzhnaya TA, Fedoseenko MV, Namazova-Baranova LS, et al. Overcoming «anti-vaccination skepticism»: searching for a solution out of the current situation. Pediatric Pharmacology. 2018;15(2):141—148. (In Russ).

45. Snegireva II, Glagolev SV, Polivanov VA, et al. Methodological recommendations for the identification, investigation and prevention of adverse events after immunization. Moscow: Ministry of Health of Russia; 2019. (In Russ).